尿路上皮癌中 m6A 修饰的现状。

The current landscape of m6A modification in urological cancers.

机构信息

Department of Urology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, China.

出版信息

PeerJ. 2023 Sep 7;11:e16023. doi: 10.7717/peerj.16023. eCollection 2023.

DOI:10.7717/peerj.16023

PMID:37701836

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10493088/

Abstract

N6-methyladenosine (m6A) methylation is a dynamic and reversible procession of epigenetic modifications. It is increasingly recognized that m6A modification has been involved in the tumorigenesis, development, and progression of urological tumors. Emerging research explored the role of m6A modification in urological cancer. In this review, we will summarize the relationship between m6A modification, renal cell carcinoma, bladder cancer, and prostate cancer, and discover the biological function of m6A regulators in tumor cells. We will also discuss the possible mechanism and future application value used as a potential biomarker or therapeutic target to benefit patients with urological cancers.

摘要

N6-甲基腺苷（m6A）甲基化是一种动态且可逆的表观遗传修饰过程。越来越多的研究表明，m6A 修饰参与了泌尿系统肿瘤的发生、发展和进展。新兴研究探讨了 m6A 修饰在泌尿系统癌症中的作用。在这篇综述中，我们将总结 m6A 修饰与肾细胞癌、膀胱癌和前列腺癌之间的关系，并发现肿瘤细胞中 m6A 调节因子的生物学功能。我们还将讨论其作为潜在生物标志物或治疗靶点用于受益泌尿系统癌症患者的可能机制和未来应用价值。